Skip to main content
S&P 5007,637.76+1.14%DOW51,778.04+0.61%NASDAQ26,418.30+1.69%BTC$76,358.00+0.81%ETH$2,445.11+2.05%GOLD$4,385.80-0.32%OIL$101.20-0.70%
Smart Investors Daily
XC

NASDAQ · XCUR

Exicure, Inc.

Healthcare · Biotechnology

$1.33

Up+$0.02 (+1.50%)

Updated Sep 17, 2026, 10:47 PM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
39.07M
P/E ratio
-4.91
Dividend yield
0.00%
52-week range
$1.05 – $9.48
Volume
21.16K
Avg. volume
653.33K

Price performance

XCUR price history

1M range · 20 trading sessions · Daily adjusted prices

XCUR closed at $1.33 after 20 trading sessions, down 8.28% for the selected period.

Last close
$1.33
Period change
-8.28%
Period low
$1.15
Period high
$1.45
Daily close
View OHLC price history
XCUR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$1.26$1.36$1.22$1.3321.16K
Sep 15, 2026$1.285$1.325$1.27$1.3117.57K
Sep 14, 2026$1.35$1.4046$1.33$1.3713.98K
Sep 11, 2026$1.40$1.43$1.3411$1.4010.54K
Sep 10, 2026$1.41$1.41$1.2553$1.3729.69K
Sep 9, 2026$1.45$1.60$1.37$1.43221.46K
Sep 8, 2026$1.31$1.5398$1.31$1.4184.09K
Sep 4, 2026$1.23$1.28$1.22$1.2516.75K
Sep 3, 2026$1.3001$1.3011$1.22$1.2321.93K
Sep 2, 2026$1.24$1.3202$1.23$1.2915.09K
Sep 1, 2026$1.28$1.30$1.2301$1.3016.73K
Aug 31, 2026$1.31$1.35$1.285$1.3121.92K
Aug 28, 2026$1.40$1.40$1.29$1.2918.88K
Aug 27, 2026$1.28$1.46$1.28$1.41102.09K
Aug 26, 2026$1.19$1.29$1.19$1.2629.74K
Aug 25, 2026$1.15$1.23$1.13$1.1919.19K
Aug 24, 2026$1.15$1.20$1.08$1.1528.82K
Aug 21, 2026$1.32$1.32$1.05$1.15151.99K
Aug 20, 2026$1.44$1.45$1.30$1.3039.01K
Aug 19, 2026$1.45$1.49$1.3971$1.4525.82K

Latest XCUR news

The latest Smart Investors Daily articles mentioning XCUR.

Stock researchCompany · Overview

XCUR research

Overview

Company profile and research snapshot.

Company profile

Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$12.00
Implied upside
—
Analysts
6
XCUR recent ratings
DateFirmRatingTarget
Aug 16, 2022Chardan CapitalNeutral—
Dec 13, 2021Chardan CapitalNeutral—
Nov 23, 2021Chardan CapitalBuy—
May 17, 2021HC Wainwright & Co.Buy—
Dec 18, 2020BMO CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 3, 2026

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties’ License and Collaboration Agreement. The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including th

Yahoo · Jun 30, 2026

Exicure Announces Board and Committee Changes

WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company") today announced changes to its Board of Directors and Board committees following actions approved by the Company's Board of Directors at its special meeting held on June 24, 2026. The Company's Board of Directors accepted the resignation of Jung Kyu Ham as a director, effective June 30, 2026. The Board also appointed Jin Young Go as a Class III director to fill the vacancy created by Mr.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By